Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost

Am J Hematol. 2021 Jan;96(1):E2-E5. doi: 10.1002/ajh.26007. Epub 2020 Oct 6.

Authors

Enrico Costa^{1

2}, Prosper Tibalinda³, Enrico Sterzi¹, Hubert M G Leufkens², Julie Makani⁴, Eliangiringa Kaale³, Lucio Luzzatto⁴

Affiliations

¹ Department of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
² Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht, The Netherlands.
³ School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
⁴ Department of Haematology, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Sickle Cell* / drug therapy
Anemia, Sickle Cell* / economics
Anemia, Sickle Cell* / epidemiology
Antisickling Agents / administration & dosage
Antisickling Agents / economics
Costs and Cost Analysis*
Female
Humans
Hydroxyurea / administration & dosage
Hydroxyurea / economics
Male
Pilot Projects
Tanzania / epidemiology

Substances

Antisickling Agents
Hydroxyurea